Clinical trial for comparative study of PDpoietin and Cinnapoietin on anemia in End Stage Renal Disease(ESRD ) patients under hemodialysis.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013080812685N2

Enrollment

Registered

2016-08-11

Start date

2016-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anemia in ESRD. Chronic kidney disease, stage 5

Interventions

Intervention 1: Intervention group 1 : Patients who will receive PD poietin: 70 units per kilogram of body weight ,weekly, in three equal divided doses will be injected intravenously after each hemodi

Treatment - Drugs

Intervention group 1 : Patients who will receive PD poietin: 70 units per kilogram of body weight ,weekly, in three equal divided doses will be injected intravenously after each hemodialysis session.

Intervention group 2 : Patients who will receive Cinna poietin: 70 units per kilogram of body weight ,weekly, in three equal divided doses will be injected intravenously after each hemodialysis sessio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: End Stage Renal Disease(ESRD ) patients under hemodialysis with hemoglobin less than 10 g/dl; Exclusion criteria: Uncontrolled Hypertention; Uncontrolled diabetes mellitus; Hospital admission in preceding month; severe hyperparathyroidism; Hemoglobinopathies; Iron deficiency anemia before treatment; Vit B12 and/ or Folic Acid deficiency before treatment; severe inflammatory state; Intolerable drug side effects during intervention

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Change in hemoglobin concentration. Timepoint: befor intervension and then monthly for three monthes during intervention. Method of measurement: by hemoglobin measurement(g/dl).	—

Secondary

Measure	Time frame
Need for packed red blood cell infusion. Timepoint: monthly during three monthes of intervention. Method of measurement: according to documents in patient's file.;Adverse drug reaction(s ). Timepoint: continous monitoring during three monthes of intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Alizaman Veismoradi

Imam Reza hospital of Kermanshah

dr.ali51071@gmail.com+98 83 3839 5886

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026